SNIP1-Related Neurodevelopmental Disorder

1. Disease Information

Overview

SNIP1‑related neurodevelopmental disorder is an autosomal recessive, congenital‑onset, multisystem neurodevelopmental syndrome caused by biallelic variants in SNIP1 (Smad nuclear interacting protein 1) at 1p34.3. To date the disorder is known essentially exclusively from a single founder missense variant, NM_024700.4:c.1097A>G, p.(Glu366Gly), segregating in Old Order Amish communities in Pennsylvania, Ohio, Indiana and Wisconsin.

The cardinal presentation is neonatal hypotonia and poor feeding, followed by severe (typically non‑verbal) global developmental delay, universally penetrant and frequently drug‑resistant epilepsy, and a recognizable craniofacial gestalt with abnormal skull shape (including multi‑suture craniosynostosis in a subset). Congenital heart defects, upper‑airway abnormalities, and hypothyroidism are common comorbidities, and early childhood mortality is substantial.

[ABSTRACT] PMID:34570759 — "Here, we describe extensive genetic studies and clinical findings of a complex inherited neurodevelopmental disorder in 35 individuals associated with a SNIP1 NM_024700.4:c.1097A>G, p.(Glu366Gly) variant, present at high frequency in the Amish community. The cardinal clinical features of the condition include hypotonia, global developmental delay, intellectual disability, seizures, and a characteristic craniofacial appearance." (Ammous Z, Rawlins LE, Jones H, et al. PLoS Genet 2021;17(9):e1009803. doi:10.1371/journal.pgen.1009803)

Key identifiers

Synonyms and alternative names

• Psychomotor retardation, epilepsy, and craniofacial dysmorphism (PMRED) — original OMIM title, still the MONDO label
• Neurodevelopmental disorder with hypotonia, craniofacial abnormalities, and seizures (NEDHCS) — current OMIM title
• SNIP1‑related neurodevelopmental disorder
• "Symptomatic epilepsy and skull dysplasia" — the clinical/laboratory name used by DDC Clinic Medical Center (Ohio Amish) for its targeted test
• Amish SNIP1 syndrome / SNIP1 Amish founder disorder (informal)

Nature of the evidence base

Information is derived almost entirely from aggregated deep‑phenotyping of individual patients in a community‑genetics setting — the Clinic for Special Children (Strasburg, PA), DDC Clinic (Middlefield, OH), and collaborating centres — rather than from EHR/claims resources. There are effectively two primary clinical publications:

1. PMID:22279524 — Puffenberger EG, Jinks RN, Sougnez C, et al. "Genetic mapping and exome sequencing identify variants associated with five novel diseases." PLoS One 2012;7(1):e28936. doi:10.1371/journal.pone.0028936 — original gene discovery (3 patients / 2 sibships).
2. PMID:34570759 — Ammous Z, Rawlins LE, Jones H, et al. PLoS Genet 2021 — definitive natural‑history cohort (51 identified, 35 deeply phenotyped).

No population registry, EHR‑based cohort, or ICEES/COHD‑style comorbidity data exist for this disorder.

2. Etiology

Primary causal factor

Genetic, monogenic, autosomal recessive. Homozygosity for SNIP1 c.1097A>G, p.(Glu366Gly) is the sole established cause.

[ABSTRACT] PMID:22279524 — "Using between 1 and 5 patient samples per disorder, we identified sequence variants in the known disease-causing genes SLC6A3 and FLVCR1, and present evidence to strongly support the pathogenicity of variants identified in TUBGCP6, BRAT1, SNIP1, CRADD, and HARS."

[BODY] PMID:22279524 — the disease locus mapped to a region containing 34 homozygous variants shared among affected individuals, of which only one — the SNIP1 change — was novel. Glu366 is highly conserved and lies in the C‑terminus, the region through which SNIP1 engages c‑Myc.

Genetic risk factors

• Causal variant: NM_024700.4:c.1097A>G (NC_000001.11:g.37537842T>C, GRCh38), p.(Glu366Gly), missense, exon 4, biallelic/homozygous. rs387906986.
• Variant classification: ClinVar germline classification "Likely pathogenic", review status 1 star (criteria provided, single submitter), last evaluated 2022‑03‑22. The 2021 PLoS Genetics authors independently assessed it as "pathogenic" under ACMG/AMP criteria. (This discrepancy should be recorded verbatim in the entry rather than resolved silently.)
• Founder effect / ancestry: essentially the only genetic "risk factor" is Old Order Amish ancestry, plus consanguinity/endogamy.
• Modifier genes: none identified. No modifier or susceptibility loci have been reported.
• Heterozygote status: carriers are unaffected; "no unaffected individuals being homozygous for this variant" [BODY, PMID:34570759] — i.e., complete penetrance in homozygotes within the studied cohort.

A second, distinct genetic mechanism (heterozygous deletion)

PMID:29726122 — Jacher JE, Innis JW. "Interstitial microdeletion of the 1p34.3p34.2 region." Mol Genet Genomic Med 2018;6(4):649–654. doi:10.1002/mgg3.409. A 2.3 Mb contiguous‑gene deletion including SNIP1 (but not AGO1, AGO3, GRIK3, SLC2A1, RIMS3) in a patient with global developmental delay, mild intellectual disability, delayed bone age, bilateral vesicoureteral reflux, vocal cord paralysis, right aberrant subclavian artery, kyphoscoliosis, bilateral metatarsus adductus, and valgus knee deformity. The authors attribute the phenotype to haploinsufficiency of the region "including the SNIP1 gene."

Curation guidance: this is a contiguous‑gene deletion syndrome, not the recessive SNIP1 disorder. Do not merge. It is at most a supporting datum that SNIP1 dosage matters, and the vocal‑cord paralysis is an intriguing partial echo of the airway phenotype. Consider a discussions entry with kind: KNOWLEDGE_GAP.

Environmental risk factors

None identified. No toxin, infectious, nutritional, occupational, parental‑age, or seasonal risk factor has been reported. Sex is not a risk factor (cohort was 19 M : 16 F).

Protective factors

None identified. No protective allele, dietary, or lifestyle factor is known. gnomAD contains no homozygotes for the variant, providing no evidence for a compensated/protected genotype.

Gene–environment interactions

Not documented for the human disorder. The nearest mechanistic analogue comes from cell biology: SNIP1's chromatin occupancy in neural progenitors is signal‑dependent — [ABSTRACT‑adjacent, BODY PMID:37553330] "TGFβ and NFκB signaling pathways control SNIP1 binding to specific gene loci in NPCs." This raises a testable (unproven) hypothesis that maternal/fetal inflammatory or TGF‑β‑modulating exposures could modify expressivity. Flag as hypothesis, not established.

3. Phenotypes

3.1 Frequency table (Ammous et al. 2021, n = 35–37 evaluated individuals)

Frequencies below are [BODY] data from the PLoS Genetics clinical tables, cross‑checked against the HPO disease annotations for OMIM:614501 (retrieved from ontology.jax.org, which encodes exact numerators/denominators).

Additional HPO terms annotated to OMIM:614501 without a cohort fraction (from the HPO disease annotation file — treat as frequency: omitted): HP:0000158 Macroglossia · HP:0000414 Bulbous nose · HP:0012802 Broad jaw · HP:0011304 Broad thumb (2/2) · HP:0002500 Abnormal cerebral white matter morphology · HP:0003429 CNS hypomyelination (2/2) · HP:0002079 Hypoplasia of the corpus callosum (2/2) · HP:0002119 Ventriculomegaly (2/2) · HP:0002353 EEG abnormality · HP:0001607 Subglottic stenosis · HP:0001647 Bicuspid aortic valve · HP:0001650 Aortic valve stenosis · HP:0000007 Autosomal recessive inheritance.

Frequency‑evidence caution (per docs/frequency-evidence-guidelines.md): the fractions above come from the HPO annotation file (which is itself derived from PMID:34570759 tables), not from an abstract sentence. Only the qualitative associations are abstract‑supported. Prefer omitting frequency: for any phenotype whose band you cannot back with a directly quotable abstract sentence.

3.2 Craniofacial gestalt (the "recognizable" feature)

[BODY] PMID:34570759 — features include "midface hypoplasia, a wide mouth with downturned corners and thin cupids bow upper lip, large tongue, high arched palate, microretrognathia (Pierre Robin sequence with or without cleft palate in three patients), malocclusion, small upturned bulbous nose, long palpebral fissures and proptosis."

Skull: "Abnormal skull shape (irregular surface, craniosynostosis)" in 100%, with "severe multi-suture craniosynostosis with Cloverleaf appearance of the skull in five individuals" [BODY].

Suggested HPO: HP:0000308 Microretrognathia · HP:0000202 Orofacial cleft / HP:0000175 Cleft palate · HP:0000463 Anteverted nares (verify) · HP:0000637 Long palpebral fissure · HP:0000520 Proptosis · HP:0000316 Hypertelorism (not reported — do not add) · HP:0011800 Midface retrusion · HP:0000687 Pierre‑Robin sequence → correct term is HP:0000201 Pierre‑Robin sequence (verify with OAK).

3.3 Neuroimaging phenotype

[BODY] PMID:34570759 — brain MRI abnormalities in ~50%, "including hydrocephalus, ventriculomegaly, white matter abnormalities, thin corpus callosum, hypomyelination, irregular cortical ribbon, Chiari malformation, absence of the septum pellucidum, hypoplastic optic nerves and septo-optic dysplasia."

Suggested HPO: HP:0000238 Hydrocephalus · HP:0002119 Ventriculomegaly · HP:0002500 Abnormal cerebral white matter morphology · HP:0002079 Hypoplasia of the corpus callosum · HP:0003429 CNS hypomyelination · HP:0002510 Chiari malformation (verify ID) · HP:0001331 Absent septum pellucidum · HP:0000633 Optic nerve hypoplasia (verify) · HP:0100842 Septo‑optic dysplasia (verify).

3.4 Epilepsy phenotype (the dominant morbidity)

[BODY] PMID:34570759 — "Seizures are a cardinal feature of the disorder with all affected individuals developing epilepsy"; types include "focal and generalised intractable seizures (myoclonic, absence, tonic-clonic) of infantile or childhood onset"; "There were no antiepileptic medications identified that consistently provide effective seizure control" and "several individuals display multiple drug resistant epilepsy."

Suggested HPO: HP:0001250 Seizure · HP:0011146 Dialeptic seizure / HP:0002121 Absence seizure · HP:0002123 Generalized myoclonic seizure · HP:0002069 Bilateral tonic‑clonic seizure · HP:0007359 Focal‑onset seizure · HP:0011171 Complex febrile seizure (not reported) · HP:0002133 Status epilepticus (management target) · HP:0011097 Epileptic spasms (not reported — do not add). Qualifiers: temporality: RECURRENT, onset: INFANTILE_ONSET/CHILDHOOD_ONSET, drug resistance is best captured in the description text.

3.5 Developmental attainment and function

[BODY] PMID:34570759 — "Global developmental delay (severe, non-verbal)" in 100%; "Most affected individuals achieved independent ambulation (age range 3–10 years), and some communicate with signs, gestures and sounds."

This is an important nuance: motor milestones are markedly delayed but often eventually achieved, while expressive language is essentially absent. Suggested HPO: HP:0011344 Severe global developmental delay · HP:0001510 Growth delay · HP:0002187 Profound global developmental delay (do not use — cohort described as "severe") · HP:0001344 Absent speech.

3.6 Quality‑of‑life impact

No formal QoL instrument (EQ‑5D, PROMIS, SF‑36, PedsQL) has been applied to this cohort. Impact must be inferred qualitatively:

• Feeding/nutrition: universal feeding difficulty with 46% pulmonary aspiration drives gastrostomy dependence — a major daily‑care burden and a driver of the recommendation for elective (rather than reactive) G‑tube placement.
• Epilepsy: drug‑resistant seizures with status‑epilepticus risk dominate family burden and healthcare utilisation.
• Communication: non‑verbal status with partial sign/gesture communication.
• Mobility: independent ambulation is attainable for most, materially better than many severe DEEs.
• Behaviour: irritability/autistic features/ADHD in 75%.

Curation note: record this as notes:/description text, not as evidence‑backed QoL claims.

4. Genetic / Molecular Information

Causal gene

SNIP1 — Smad nuclear interacting protein 1; hgnc:30587; OMIM:608241; 1p34.3; Entrez 79753; ENSG00000163877; UniProt Q8TAD8 (396 aa, 45,778 Da). Previous/alias symbol: PML1 (yeast Pml1p homolog).

Protein architecture (UniProt Q8TAD8): - N‑terminal nuclear localisation signal; the N‑terminal region mediates Smad and RelA/p65 binding - Forkhead‑associated (FHA) domain, residues 281–344 — a phospho‑threonine‑peptide recognition module - C‑terminus (containing Glu366) mediates c‑Myc interaction - PTMs: phosphorylation (Ser35, Ser49, Ser52, Ser54, Thr57, Ser58, Ser202, Ser394); SUMOylation (Lys30, Lys108, Lys223) - Subcellular localisation: nucleus / nucleoplasm (GO:0005654)

Pathogenic variant

Allele frequency

• gnomAD: [BODY, PMID:34570759] "allele frequency of 0.001% with 11 heterozygotes (10 Amish) and no homozygous individuals listed."
• Old Order Amish (Puffenberger 2012, control chromosomes): 5/203 = 2.5% carrier frequency [BODY]
• Old Order Amish (Ammous 2021): allele frequency 0.5% (Pennsylvania) to 1.4% (Ohio/Indiana/Wisconsin) [BODY]
• GeneReviews (Wallace SE, Puffenberger EG, Bean LJH; "Genetic Disorders Associated with Founder Variants Common in the Amish Population," last update 2023‑12‑07; NBK558237): carrier frequency 1/34 in Old Order Amish; this variant accounts for ~100% of pathogenic SNIP1 variants identified in this population.

Note the internal inconsistency across sources (2.5% vs 0.5–1.4% vs 1/34 ≈ 2.9%). These are different sampling frames (small control panel vs settlement‑stratified vs GeneReviews summary). Record each with its own prevalence/case_fractions record, population stratifier, and evidence — do not average them.

Functional consequences of p.Glu366Gly

Three independent lines of evidence, all pointing to partial (hypomorphic) loss of function, not a null:

1. Protein instability and mislocalisation (in vitro, 2012). [BODY, PMID:22279524] The mutant showed abnormal nuclear localisation with "a more aggregated appearance" versus wild‑type's punctate pattern; western blot band density was "84.9±9.6% SD lower than wild-type" — i.e. ~85% reduction in steady‑state protein.
2. Conservation and domain proximity. [BODY, PMID:34570759] "The p.(Glu366Gly) SNIP1 amino acid substitution is located in close proximity to the forkhead association (FHA) domain," a "functionally important region of SNIP1"; the authors caution "this Amish variant may be unlikely to result in complete loss of function." (Note the UniProt FHA boundary is 281–344, so E366 sits just C‑terminal to the annotated domain; the 2026 Nature Communications paper below treats E366G as an FHA‑domain mutation. Record the discrepancy rather than picking a side.)
3. Direct splicing‑machinery defect (2026, definitive). [ABSTRACT] PMID:41904131 — "Mutations in SNIP1 FHA domain, including the neurodevelopmental disorder-associated E366G variant, impair P-SF3B1 binding, pre-mRNA splicing, and cell viability." (Gajdušková P, Ruiz de Los Mozos I, Hluchý M, et al. "Phosphorylation of SF3B1 by CDK11 orchestrates spliceosome activation via SNIP1‑dependent RES complex recruitment." Nat Commun 2026. doi:10.1038/s41467-026-71119-2)

Mechanistic classification for the KB: LOSS_OF_FUNCTION (hypomorphic/partial). Complete LoF is presumably embryonic‑lethal — consistent with mouse homozygous null prenatal lethality (§15).

Modifier genes

None reported. The remarkable clinical homogeneity of the Amish cohort (single variant, shared genetic background) both explains the absence of modifier data and makes this disorder a poor discovery substrate for modifiers.

Epigenetic information

Two distinct senses, both relevant:

1. SNIP1 as an epigenetic regulator (mechanism, not biomarker). [ABSTRACT] PMID:37553330 — "SNIP1 facilitates the genomic occupancy of Polycomb complex PRC2 and instructs H3K27me3 turnover at target genes." SNIP1 also recruits TET2 to c‑MYC target genes (PMID:30404004, "SNIP1 Recruits TET2 to Regulate c-MYC Target Genes and Cellular DNA Damage Response," Cell Rep 2018) — a direct link to DNA 5‑hydroxymethylation.
2. Episignature / methylation biomarker for diagnosis: none published. SNIP1 is not among the genes with a validated DNA‑methylation episignature (EpiSign). Curation gap.

Chromosomal abnormalities

• No aneuploidy, translocation, or inversion associated with the recessive disorder.
• 1p34.3p34.2 interstitial microdeletion encompassing SNIP1 (PMID:29726122) — see §2. Relevant to CMA interpretation.

5. Environmental Information

• Environmental factors: none identified. No CTD entry links an environmental chemical to this disorder.
• Lifestyle factors: not applicable — congenital monogenic disorder.
• Infectious agents: not causal. However, infection is a leading proximate cause of death (see §11) and recurrent aspiration/respiratory infection is a major secondary morbidity — model this as a downstream consequence node, not an etiologic node.

6. Mechanism / Pathophysiology

6.1 SNIP1 protein: four functional arms

[ABSTRACT] PMID:34570759 — "SNIP1 (Smad nuclear interacting protein 1) is a widely expressed transcriptional suppressor of the TGF-β signal-transduction pathway which plays a key role in human spliceosome function."

[ABSTRACT] PMID:38304835 (Chen Y, Guo W, Guo X, Wanqing Q, Yin Z. "The clinical utilization of SNIP1 and its pathophysiological mechanisms in disease." Heliyon 2024;10(2):e24601) — "Smad intranuclear binding protein 1 (SNIP1), a highly conserved nuclear protein, functions as a transcriptional regulator and exerts a significant influence on disease progression. In addition, the N-terminal domain of SNIP1 facilitates its interaction with Smad4, a signaling protein associated with the TGF-β family, and RelA/p65, a transcription factor connected to NF-κB. This interaction further enhances the transcriptional activation of c-Myc-dependent genes."

6.2 The splicing arm — the most direct route from E366G to disease

[ABSTRACT] PMID:41904131 — "We further demonstrate that P-SF3B1 is recognized by forkhead-associated (FHA) domain of SNIP1, which promotes recruitment of retention and splicing (RES) complex during spliceosome activation. Acute SNIP1 depletion disrupts RES incorporation, causes widespread splicing defects, and promotes hyperphosphorylation of SF3B1 by CDK11."

[ABSTRACT] PMID:37027487 (Meng D, Zheng Q, Zhang X, Piao X, Luo L, Jia Y. "A molecular brake that modulates spliceosome pausing at detained introns contributes to neurodegeneration." Protein Cell 2023;14(1):27–53. doi:10.1093/procel/pwac008) — "Here, we suggest that post-transcriptional DI splicing is paused at the Bact state, an active spliceosome but not catalytically primed, which depends on Smad Nuclear Interacting Protein 1 (SNIP1) and RNPS1 (a serine-rich RNA binding protein) interaction… Snip1 conditional knockout in the cerebellum decreases DI splicing efficiency and causes neurodegeneration."

This places SNIP1 alongside other spliceosomopathy neurodevelopmental genes (EFTUD2, SF3B4, SNW1, SF3B1, RNU4‑2) — a useful cross‑entry link in dismech, and arguably a candidate future mechanism module ("spliceosomopathy neurodevelopment").

6.3 The neural‑progenitor survival arm

[ABSTRACT] PMID:37553330 (Matsui Y, Djekidel MN, Lindsay K, et al. "SNIP1 and PRC2 coordinate cell fates of neural progenitors during brain development." Nat Commun 2023;14:4771. doi:10.1038/s41467-023-40487-4) — "Here, we report that Smad nuclear interacting protein 1 (SNIP1) promotes neural progenitor cell survival and neurogenesis and is, therefore, integral to brain development. The SNIP1-depleted brain exhibits dysplasia with robust induction of caspase 9-dependent apoptosis. Mechanistically, SNIP1 regulates target genes that promote cell survival and neurogenesis, and its activities are influenced by TGFβ and NFκB signaling pathways. Further, SNIP1 facilitates the genomic occupancy of Polycomb complex PRC2 and instructs H3K27me3 turnover at target genes. Depletion of PRC2 is sufficient to reduce apoptosis and brain dysplasia and to partially restore genetic programs in the SNIP1-depleted brain in vivo."

Supporting [BODY] detail from the same paper: "By E15, Snip1_Nes-KO embryos displayed severe thinning of brain tissues and dysplasia with 100% penetrance"; SOX2⁺ neural progenitor cells, and TBR2⁺ and INSM1⁺ intermediate progenitors "were markedly reduced"; "All ventricles of Snip1_Nes-KO displayed strong induction of cl-caspase 3"; "inhibition of caspase 9 robustly reduced apoptosis" whereas caspase 8 inhibition "modestly altered apoptosis"; EED (PRC2) depletion "reduced apoptosis and rescued NPCs."

6.4 Patient transcriptome (human, in vivo)

[BODY] PMID:34570759 — differential expression analysis of patient samples identified "75 significantly upregulated genes, and 109 significantly downregulated genes" (FDR <0.05). Reactome analysis: "the most overrepresented pathway was the TGF-β receptor signalling in epithelial to mesenchyme pathway." Five seizure‑associated genes were notably altered: ROBO1, SOX5, CNTNAP2, PAFAH1B1, TSNARE1 (ROBO1 most upregulated); SYT1 (synaptic vesicle) also dysregulated; 24 differentially expressed genes had "a previously established association with neurological disease." Additional dysregulated pathways reported in the paper's discussion include NOTCH3 signalling and the MYC pathway.

6.5 Proposed causal chain (for pathophysiology nodes)

[MOLECULAR] SNIP1 p.Glu366Gly homozygosity
   → reduced SNIP1 protein abundance (~85% ↓) + nuclear aggregation
   → impaired FHA-domain recognition of phospho-SF3B1
├─→ [MOLECULAR] failed RES complex recruitment / spliceosome activation defect
│        → aberrant pre-mRNA splicing, detained-intron mishandling
└─→ [MOLECULAR] dysregulated SNIP1-dependent transcription
         (de-repressed TGF-β/SMAD; de-repressed NF-κB/RELA-p300;
          altered c-MYC target output; mislocalised PRC2 → aberrant H3K27me3)
   → [CELLULAR] neural progenitor cell (SOX2+, TBR2+, INSM1+) apoptosis
via the intrinsic, caspase-9-dependent pathway; reduced neurogenesis
   → [TISSUE] cortical dysplasia, hypomyelination, corpus callosum hypoplasia,
ventriculomegaly, midline defects; abnormal cranial suture fusion;
abnormal pharyngeal/laryngeal and cardiac morphogenesis
   → [ORGANISM] severe global developmental delay, intractable epilepsy,
craniofacial gestalt, airway compromise, CHD, early mortality

Upstream vs downstream: the molecular splicing/transcription lesion is upstream; NPC apoptosis is the pivotal cellular hub (the point at which PRC2 depletion rescues, in mouse); tissue malformation and epilepsy are downstream.

6.6 Suggested ontology terms

GO biological process (all verified against QuickGO): - GO:0000398 mRNA splicing, via spliceosome — modifier DECREASED/ABNORMAL - GO:0007179 transforming growth factor beta receptor signaling pathway — INCREASED (de‑repression) - GO:0043122 regulation of canonical NF-kappaB signal transduction — INCREASED - GO:0097193 intrinsic apoptotic signaling pathway — INCREASED - GO:0021895 cerebral cortex neuron differentiation — DECREASED - GO:0006974 DNA damage response - Additional candidates to verify with OAK: GO:0050768 negative regulation of neurogenesis; GO:0006355 regulation of DNA-templated transcription; GO:0035914? (n/a)

GO cellular component (verified): GO:0005681 spliceosomal complex · GO:0031519 PcG protein complex · GO:0005654 nucleoplasm (verify).

Cell Ontology (verified via OLS): - CL:0011020 neural progenitor cell - CL:0000681 radial glial cell - CL:0013000 forebrain radial glial cell - CL:0000047 neuronal stem cell (verify) - CL:0000540 neuron (verify)

CHEBI: not applicable — no small‑molecule metabolite is central to the mechanism.

6.7 Metabolic, immune, and biochemical dimensions

• Metabolic changes: no primary inborn‑error‑of‑metabolism component. Hypoglycaemia in ~20% is documented but its mechanism is unexplained (feeding failure? endocrine?) — record as an unexplained finding / knowledge gap, not as a metabolic mechanism.
• Immune system involvement: no immunodeficiency or autoimmunity. SNIP1 is an NF‑κB brake and has documented roles in intestinal epithelial barrier/inflammation (PMID:29426045, Mucosal Immunol 2018) and osteoarthritis inflammation (PMID:37739115), but no immune phenotype has been reported in patients. Do not over‑extrapolate.
• Tissue damage mechanisms: developmental (apoptotic loss of progenitors + malformation), not degenerative — with the important caveat that the Protein Cell 2023 cerebellar cKO shows SNIP1 loss can also drive post‑developmental neurodegeneration, raising an untested question about whether adolescents/adults with the disorder have a degenerative component.
• Biochemical abnormalities: hypothyroidism (25%) is the one reproducible laboratory abnormality; hypoglycaemia (~20%). No specific enzyme deficiency, receptor, or ion‑channel defect.

6.8 Molecular profiling summary

7. Anatomical Structures Affected

Organ level

Primary: - Brain UBERON:0000955 — cerebral cortex UBERON:0000956, cerebral white matter UBERON:0002437(verify), corpus callosum UBERON:0002336, lateral ventricle UBERON:0002285, septum pellucidum UBERON:0002094(verify), cerebellum UBERON:0002037 (mouse degeneration data), optic nerve UBERON:0000941 - Cranium / skull UBERON:0003128 — cranial suture UBERON:0006842(verify) - Face / craniofacial skeleton — mandible UBERON:0001684, palate UBERON:0001716, tongue UBERON:0001723, lip UBERON:0001833, nose UBERON:0000004

Secondary / systemic: - Heart UBERON:0000948 — interatrial septum, interventricular septum, aorta UBERON:0000947, aortic valve UBERON:0002137, left ventricular myocardium (non‑compaction) - Larynx UBERON:0001737 (laryngomalacia, subglottic stenosis) - Lung / respiratory system UBERON:0001004 (aspiration, pneumonia) - Thyroid gland UBERON:0002046 (hypothyroidism) - Ear / middle ear UBERON:0001756 (conductive hearing loss) - Eye UBERON:0000970 (nystagmus, strabismus, optic nerve hypoplasia) - Hand / digits UBERON:0002398 (short palms, tapered fingers, broad thumbs) - Abdominal wall (umbilical hernia); foot (talipes)

Body systems: nervous (central and peripheral reflex arc), musculoskeletal/craniofacial, cardiovascular, respiratory/upper airway, endocrine, gastrointestinal (feeding), sensory.

Tissue and cell level

• Neuroepithelium / ventricular and subventricular zone — the primary site of the cellular lesion
• Neural progenitor cells CL:0011020; radial glia CL:0000681 / CL:0013000; intermediate (basal) progenitors (TBR2⁺/INSM1⁺ — no precise CL term; use CL:0011020 with a more specific preferred_term)
• Neurons — reduced production; oligodendrocytes/myelin — hypomyelination
• Cranial suture osteogenic tissue — premature fusion
• Cardiac septal/valvular mesenchyme — CHD
• Laryngeal cartilage/connective tissue — laryngomalacia

Subcellular level

• Nucleus / nucleoplasm GO:0005654 — primary site of SNIP1 action
• Spliceosomal complex GO:0005681 — the direct molecular machine affected
• PcG protein complex (PRC2) GO:0031519
• Mitochondrion — indirectly, via the intrinsic (caspase‑9/apoptosome) apoptotic pathway GO:0097193

Localization / lateralization

Bilateral and symmetric throughout (brain malformations, craniosynostosis, hand anomalies, nystagmus/strabismus). No lateralized or asymmetric pattern reported. Cloverleaf skull reflects multi‑suture, bilateral synostosis.

8. Temporal Development

Onset

• Congenital / neonatal. Hypotonia and poor feeding are apparent in early infancy; the HPO annotation explicitly records onset = "Early infancy" for feeding difficulties.
• 54% are small for gestational age, indicating prenatal growth effects.
• Onset pattern: congenital and insidiously evolving — the craniofacial gestalt is described as evolving over time ("Dysmorphic features that evolve over time…" [BODY, PMID:22279524]), so the disorder may be less recognisable in the neonatal period than in later childhood.
• Seizure onset: infantile or childhood.

Suggested HPO onset terms: HP:0003577 Congenital onset · HP:0003623 Neonatal onset · HP:0003593 Infantile onset.

Progression

• Course: static‑encephalopathy‑like in its developmental substrate, but with progressive craniofacial/skull features, progressive epilepsy burden in some, and cumulative complications (aspiration, airway, cardiomyopathy).
• Rate: slow; developmental gains continue (ambulation achieved between ages 3 and 10 years).
• Duration: chronic, lifelong; not self‑limited.
• Stages: no formal staging system exists. A practical framing: (i) neonatal — hypotonia/feeding/airway; (ii) infancy–early childhood — seizure onset, skull evolution, CHD management; (iii) mid‑childhood — motor gains, behavioural phenotype, drug‑resistant epilepsy; (iv) adolescence/adulthood — poorly characterised (oldest patient in the 2021 cohort was 26 years).

Patterns

• Remission: none. No spontaneous or treatment‑induced remission of the core phenotype. Seizures are not reliably remitting.
• Critical periods / windows of intervention:
• Prenatal/early embryonic — the true window for the neurodevelopmental lesion (mouse dysplasia is established by E15); realistically unreachable therapeutically.
• Neonatal — airway and feeding intervention; newborn hearing screen; echocardiogram.
• Infancy — early EEG and anticonvulsant optimisation (explicitly recommended to prevent status epilepticus and treat apnoea).
• Infancy–early childhood — craniosynostosis surgical timing.
• Ongoing — thyroid surveillance, cardiomyopathy surveillance.

9. Inheritance and Population

Epidemiology

• Prevalence: not formally estimated. No population prevalence figure exists. The disorder is ultra‑rare worldwide and effectively population‑restricted to Old Order Amish.
• Cases described: 51 affected individuals of Old Order Amish descent identified across 21 families / 27 sibships, of whom 35 were clinically evaluated (19 M, 16 F), age range 1 month – 26 years [BODY, PMID:34570759]; plus 3 individuals from 2 sibships in the original 2012 report (overlapping cohort).
• Recommended dismech Prevalence records:
• measure_type: CASES_IN_LITERATURE, prevalence_class: ULTRA_RARE, population: Worldwide, notes: 51 affected individuals identified (Ammous 2021).
• measure_type: CARRIER_FREQUENCY, population: Old Order Amish, rate_per_100000: 2941 (1/34 ≈ 2.94%), source GeneReviews NBK558237.
• measure_type: CARRIER_FREQUENCY, population: Old Order Amish control chromosomes (Puffenberger 2012), 5/203 chromosomes = 2.5% allele‑carrier estimate.
• Allele‑frequency records for PA Amish (0.5%) vs OH/IN/WI Amish (1.4%).
• Incidence: not reported. A rough derivation from a 1/34 carrier frequency under random mating within the community gives an expected affected‑birth rate of ~1/4,600 — do not curate this as a sourced figure; it is an inference, and Amish mating is not random.

Inheritance

• Pattern: Autosomal recessive — HPO HP:0000007; suggested GENO/inheritance binding per dismech Inheritance class with inheritance_term = HP:0000007 and term: populated.
• Penetrance: complete in homozygotes within the studied cohort — "no unaffected individuals being homozygous for this variant" [BODY, PMID:34570759].
• Expressivity: variable but with an invariant core. Eight features are 100% penetrant (GDD, hypotonia, hyporeflexia, seizures, feeding difficulties, abnormal skull shape, high palate, wide mouth/cupid's bow); the variable features are cardiac, endocrine, airway, ophthalmologic and MRI findings. Cloverleaf skull occurred in only 5 individuals — the most striking intra‑genotype variability.
• Anticipation: not applicable (not a repeat‑expansion disorder).
• Germline mosaicism: not reported.
• Founder effect: yes — this is the defining epidemiological feature. A single Amish founder haplotype accounts for ~100% of pathogenic SNIP1 alleles in this population.
• Consanguinity: central. The disorder was mapped by autozygosity/homozygosity mapping in an endogamous population; all patients are homozygous by descent.
• Carrier frequency: 1/34 Old Order Amish (GeneReviews 2023).

Population demographics

• Affected populations: Old Order Amish (Pennsylvania; Ohio/Indiana/Wisconsin settlements). gnomAD contains 11 heterozygotes, 10 of whom are Amish — i.e., the variant is essentially absent from non‑Amish populations.
• Geographic distribution: Lancaster County PA; Geauga County OH and related Midwest settlements. The allele frequency differs ~3‑fold between settlements (0.5% PA vs 1.4% OH/IN/WI), a classic sub‑founder‑effect signal.
• Sex ratio: ~1:1 (19 M : 16 F in the evaluated cohort) — consistent with autosomal inheritance.
• Age distribution: paediatric‑weighted; 1 month to 26 years in the reported cohort. Adult natural history is essentially undescribed — a major knowledge gap.

10. Diagnostics

Clinical tests

Biomarkers: none. No circulating protein, metabolite, or imaging biomarker is validated. Curation gap.

Genetic testing

Recommended approach, tiered:

1. Targeted single‑variant testing for SNIP1 c.1097A>G in any Plain‑community child with the phenotype. A dedicated clinical assay exists: DDC Clinic Laboratory, "Symptomatic Epilepsy and Skull Dysplasia (SNIP1) Targeted Testing." Amish/Mennonite multi‑variant founder panels (Clinic for Special Children, DDC Clinic) also include it. This is the highest‑yield, lowest‑cost first‑line test in the at‑risk population, and the GeneReviews Amish founder‑variant chapter lists it accordingly.
2. Exome (WES) or genome (WGS) sequencing for non‑Plain patients or phenotype‑first presentations — this is how the gene was discovered (WES at the Broad Institute, PMID:22279524) and remains the only route to identify hypothetical non‑founder SNIP1 alleles.
3. Epilepsy / intellectual‑disability gene panels — SNIP1 is included on many commercial NDD and epilepsy panels (see NCBI GTR, "Clinical and research tests for SNIP1").
4. Chromosomal microarray (CMA) — relevant for detecting 1p34.3p34.2 deletions encompassing SNIP1 (PMID:29726122), a different mechanism/phenotype.
5. Karyotype, FISH, mtDNA testing, repeat‑expansion testing: not indicated.
6. SNP‑array autozygosity mapping — the research method that mapped the locus; still relevant in consanguineous families with unsolved phenotypes.

Omics‑based diagnostics

• RNA sequencing: research‑grade only. Patient transcriptome signatures (TGF‑β EMT pathway, ROBO1/CNTNAP2/PAFAH1B1) are not validated as a diagnostic assay. Given the splicing mechanism (§6.2), RNA‑seq for aberrant splicing/detained‑intron signatures is a plausible but unvalidated future diagnostic — worth recording as a discussions KNOWLEDGE_GAP with proposed experiments.
• Proteomics / metabolomics / epigenomics / liquid biopsy: none available or applicable.

Clinical criteria

No formal consensus diagnostic criteria (no DSM/ICD/society guideline) exist. Diagnosis is molecular, supported by a recognisable gestalt. Practical criteria: Old Order Amish ancestry + neonatal hypotonia/poor feeding + severe non‑verbal GDD + epilepsy + wide mouth/cupid's‑bow/high palate/abnormal skull shape → targeted SNIP1 testing.

Differential diagnosis

Screening

• Newborn screening: SNIP1 is not on any state NBS panel and the disorder is not NBS‑amenable (no biochemical marker). However, the failed newborn hearing screen in 21% is a real incidental ascertainment route.
• Carrier screening: highly appropriate and actively practiced — the variant is on Plain‑community founder‑variant carrier panels (Clinic for Special Children; DDC Clinic).
• Cascade screening: standard for at‑risk siblings and extended family in an endogamous pedigree structure.

11. Outcome / Prognosis

Survival and mortality

[BODY] PMID:34570759 — "Six children died between ages 9 months and 11 years as a consequence of infection, sudden cardiopulmonary arrest, or accidental drowning."

• Case fatality in the reported cohort: 6 deaths among the evaluated individuals — ≈17% mortality in a cohort spanning 1 month to 26 years. This is a crude, non‑actuarial figure; no Kaplan–Meier survival curve, 5‑/10‑year survival rate, or life‑expectancy estimate has been published.
• Causes of death (all three named): infection; sudden cardiopulmonary arrest; accidental drowning.
• Disease‑specific mortality mechanisms: aspiration/respiratory infection (46% aspiration rate, 75% upper‑airway abnormality), cardiac (CHD in 60%, LVNC cardiomyopathy in 12% — the plausible substrate for "sudden cardiopulmonary arrest"), and seizure‑related risk (status epilepticus; drowning during an unwitnessed seizure is a well‑recognised epilepsy mortality mode). SUDEP is not explicitly invoked by the authors — do not assert it.
• Survival to at least 26 years is documented.

Morbidity and function

• Cognitive: severe intellectual disability, non‑verbal.
• Motor: most achieve independent ambulation (ages 3–10 years) — a meaningfully better motor outcome than the cognitive outcome.
• Communication: some use signs, gestures, and sounds; no spoken language.
• Feeding: universal difficulty; gastrostomy dependence common.
• Disability outcome: lifelong, profound dependence for self‑care; ICF‑level severe activity limitation across learning, communication, and self‑care domains.
• Quality‑of‑life instruments: none applied. No EQ‑5D, PedsQL, PROMIS, or disease‑specific measure has been reported.

Complications

Recurrent respiratory infection and pneumonia (aspiration‑driven); status epilepticus; apnoea (infancy); airway obstruction (laryngomalacia, subglottic stenosis); congestive heart failure/arrhythmia risk from CHD and LVNC; raised intracranial pressure and secondary visual/neurological compromise from multi‑suture craniosynostosis; hydrocephalus; hypothyroidism; hypoglycaemia; conductive hearing loss; failure to thrive; orthopaedic sequelae (talipes, kyphoscoliosis in the deletion case).

Recovery potential

None. No recovery or reversal of the neurodevelopmental phenotype is possible; management is entirely supportive and complication‑preventive.

Prognostic factors

Not formally studied. Clinically plausible (and explicitly targeted by the authors' management recommendations) determinants of outcome: severity/multiplicity of craniosynostosis, presence and severity of CHD or cardiomyopathy, degree of airway compromise and aspiration, and seizure control. Prognostic biomarkers: none. All of the above should be recorded as clinical reasoning, not as evidenced prognostic factors.

12. Treatment

There is no disease‑modifying or targeted therapy. Management is entirely supportive, anticipatory, and multidisciplinary. The 2021 PLoS Genetics paper is the only source of formal management recommendations.

Key management recommendations (from PMID:34570759, [BODY])

• "elective gastrostomy tube placement to support growth and limit pulmonary aspiration"
• "careful optimisation of anticonvulsant medications to treat apnea in infancy, maintain seizure control, and prevent status epilepticus"
• "EEG should be obtained at an early stage"
• "Neuroimaging should be performed at diagnosis, and echocardiogram should be undertaken to screen for congenital heart defects"

Treatment table with suggested NCIT annotations

Pharmacogenomics

None established. No SNIP1‑specific PGx guidance (no CPIC/PharmGKB entry). Standard antiseizure‑drug PGx caveats apply generically (e.g. HLA‑B15:02 and carbamazepine), but are not disorder‑specific* — do not curate as SNIP1‑related.

Advanced therapeutics

• Gene therapy / gene editing: none; not in preclinical development for this indication.
• ASO / RNA therapy: none. Note the conceptual tension: the pathogenic mechanism is a splicing‑machinery defect (trans‑acting), not a cis‑acting splice variant, so classical exon‑skipping ASO logic does not apply. Do not associate this entry with the antisense_oligonucleotide_therapy module.
• Cell therapy, immunotherapy, targeted small molecules: none.
• Theoretical target from mouse work: the Nat Commun 2023 finding that PRC2 (EED) depletion rescues apoptosis and brain dysplasia in Snip1‑null mouse brain identifies PRC2/EZH2 inhibition as a mechanistically motivated but entirely unproven therapeutic hypothesis. There is no human, in‑vivo‑disease, or translational evidence, and the rescue was in a null (not E366G) background during embryonic development — a window that is not clinically actionable. Record as a mechanistic_hypotheses entry with status: EMERGING and a HUMAN_MODEL_MISMATCH discussion, not as a treatment.

Clinical trials

A ClinicalTrials.gov API v2 query for "SNIP1" returned zero studies (retrieved 2026‑08‑01). No interventional or observational trial is registered for this disorder.

Treatment outcomes

• Response rates: not reported for any intervention. The single explicit efficacy statement is a negative one — no antiepileptic provides consistent seizure control.
• Adverse events: no disorder‑specific AE data. Standard risks of gastrostomy, craniofacial surgery, and antiseizure polypharmacy apply.

Treatment strategy

No published algorithm. The de‑facto pathway from the 2021 paper: molecular diagnosis → baseline EEG + brain MRI + echocardiogram → airway and swallow assessment → early elective gastrostomy → anticonvulsant optimisation → craniofacial surgical assessment → thyroid surveillance → developmental therapies → genetic counselling and family carrier testing. Personalised‑medicine approaches beyond genotype‑confirmed diagnosis: none.

13. Prevention

Primary prevention

Not possible for an affected conceptus. Population‑level primary prevention operates entirely through reproductive genetics: - Carrier screening in Plain communities (Clinic for Special Children, DDC Clinic founder‑variant panels) — high yield given a 1/34 carrier frequency. - Genetic counselling with 25% sibling recurrence risk. - Reproductive options: partner carrier testing, prenatal diagnosis (CVS/amniocentesis targeted variant testing), preimplantation genetic testing for monogenic disease (PGT‑M) where culturally acceptable. (Note: uptake of PGT‑M and pregnancy termination is culturally constrained in Plain communities; counselling in these communities is typically framed around informed reproductive decision‑making and preparedness, not termination.)

Secondary prevention (early detection)

• Cascade/at‑birth targeted testing in known carrier families, enabling neonatal anticipatory care rather than diagnostic odyssey.
• The 2021 recommendations are essentially a secondary‑prevention program: early EEG, baseline neuroimaging, screening echocardiogram, hearing screen, thyroid function testing, swallow assessment.

Tertiary prevention (complication prevention) — the highest‑value tier here

• Elective (pre‑emptive) gastrostomy to prevent aspiration pneumonia and growth failure — this is an explicit prevention‑framed recommendation.
• Anticonvulsant optimisation to prevent status epilepticus and treat infantile apnoea.
• Water safety supervision — accidental drowning was one of three named causes of death in a cohort where every patient has epilepsy. This is an obvious, concrete, family‑level preventive measure, though it is not stated as a formal recommendation in the paper.
• Cardiac surveillance for CHD and LVNC cardiomyopathy.
• Thyroid surveillance for treatable hypothyroidism.
• Airway surveillance and timely ENT intervention.
• ICP monitoring / timely craniofacial surgery in multi‑suture synostosis.

Immunization

No disease‑specific vaccine. Routine and enhanced immunisation (influenza, pneumococcal, RSV) is clinically important given aspiration risk and infection as a leading cause of death — but this is general good practice, not a published disorder‑specific recommendation. Suggested NCIT if curated: NCIT:C15346 Vaccination, therapeutic_modality: VACCINE. Note: vaccination coverage is historically lower in some Plain communities, which is a real public‑health consideration for this population.

Public health / environmental interventions

Community‑partnered genetics services (the Clinic for Special Children / DDC Clinic model) are the operative public‑health intervention: low‑cost founder‑variant testing embedded in a trusted community clinic. No environmental intervention applies.

14. Other Species / Natural Disease

Taxonomy and orthologs

Breed

Not applicable — no VBO breed association; no domestic‑animal breed disorder is known.

Natural disease in other species

None identified. Targeted searching found no OMIA entry for SNIP1 in any species — no naturally occurring SNIP1‑related disease is recorded in dogs, cattle, horses, or other domestic animals as of this search. All animal data are experimentally induced (§15).

Caveat: this is a "not found in search" result, not a proof of absence. Curate as "no naturally occurring animal disease reported" rather than as a positive negative.

Comparative biology and evolutionary conservation

• SNIP1 is deeply conserved — described as "a highly conserved nuclear protein" [ABSTRACT, PMID:38304835]. Glu366 itself is "highly conserved" across species [BODY, PMID:22279524], which is the conservation argument underpinning pathogenicity.
• The RES complex (Bud13p/Pml1p/Snu17p) is conserved from yeast to vertebrates, and its splicing function is conserved: [ABSTRACT, PMID:29969449] "The retention and splicing (RES) complex is formed by three different proteins (Bud13p, Pml1p and Snu17p) and is involved in splicing in yeast."
• The neurodevelopmental requirement is conserved across vertebrates — zebrafish snip1 mutants and mouse Snip1 conditional knockouts both show excess brain cell death and reduced neurogenesis (see §15), matching the human cortical/midline malformation phenotype. This cross‑species convergence is the single strongest argument that the human disorder is a neural‑progenitor‑survival disease.
• Divergence to note: mouse Snip1 null is prenatally lethal, whereas humans homozygous for E366G survive to adulthood — consistent with E366G being hypomorphic rather than null. This is a genuine human‑model mismatch to record.

Transmission

Not applicable — non‑infectious, non‑zoonotic, no cross‑species susceptibility.

15. Model Organisms

15.1 Mouse (Mus musculus) — the principal model

MGI:2156003, Snip1, chromosome 4. MGI records 15 mutations/alleles: 1 ENU chemically induced, 2 other chemically induced, 5 endonuclease‑mediated, 1 gene‑trapped, 1 radiation‑induced, 5 targeted, 4 genomic mutations.

Constitutive null — IMPC / MGI:

"Mice homozygous for a knock-out allele exhibit prenatal lethality." (MGI phenotype summary)

IMPC data for Snip1^tm1a(EUCOMM)Wtsi:

(Note the heterozygous neurological/ocular signals — "abnormal tail movements," "abnormal placement of pupils" — which weakly echo the human nystagmus/strabismus and neurological phenotype and support dosage sensitivity. Treat as suggestive only; IMPC het findings are noisy.)

Conditional neural knockout — the disease‑relevant model (PMID:37553330): - Allele/driver: Snip1-tm1a (Infrafrontier/EMMA 04224) → crossed to Actin‑FLPe to make Snip1‑flox → crossed to Nestin‑Cre = Snip1_Nes-KO (neural‑progenitor‑specific deletion) [BODY] - Phenotype: "By E15, Snip1_Nes-KO embryos displayed severe thinning of brain tissues and dysplasia with 100% penetrance" [BODY] - Cellular: marked reduction of SOX2⁺ NPCs and TBR2⁺ / INSM1⁺ intermediate progenitors; strong cleaved‑caspase‑3 induction in all ventricles; caspase‑9 inhibition robustly reduced apoptosis (caspase‑8 only modestly) [BODY] - Rescue: [ABSTRACT] "Depletion of PRC2 is sufficient to reduce apoptosis and brain dysplasia and to partially restore genetic programs in the SNIP1-depleted brain in vivo."

Conditional cerebellar knockout — neurodegeneration model (PMID:37027487): - [ABSTRACT] "Haploinsufficiency of Snip1 attenuates neurodegeneration and globally rescues IDT accumulation caused by a previously reported mutant U2 snRNA, a basal spliceosomal component. Snip1 conditional knockout in the cerebellum decreases DI splicing efficiency and causes neurodegeneration." - Note the bidirectional result: Snip1 haploinsufficiency is protective in a mutant‑U2 neurodegeneration background, while cerebellar Snip1 cKO is causative. This is a genuinely non‑trivial dose/context dependency worth capturing as a mechanistic_hypotheses nuance.

15.2 Zebrafish (Danio rerio)

PMID:29969449 — Fernandez JP, Moreno‑Mateos MA, Gohr A, et al. "RES complex is associated with intron definition and required for zebrafish early embryogenesis." PLoS Genet 2018;14(7):e1007473. doi:10.1371/journal.pgen.1007473

[ABSTRACT] "In this study, we have generated loss-of-function mutants for the three components of the RES complex in zebrafish and showed that they are required during early development. The mutants showed a marked neural phenotype with increased cell death in the brain and a decrease in differentiated neurons. Transcriptomic analysis of bud13, snip1 (pml1) and rbmx2 (snu17) mutants revealed a global defect in intron splicing, with strong mis-splicing of a subset of introns."

This is the most phenotype‑congruent model for the human brain phenotype at the whole‑organism level: brain‑specific cell death + reduced neuron production + global splicing defect, all in one organism, and it independently corroborates the mouse NPC‑apoptosis result via a completely different route (splicing rather than PRC2).

15.3 Cellular / in vitro systems

• HEK293/HeLa transfection studies of the E366G mutant (PMID:22279524) — showed nuclear aggregation and ~85% reduced protein abundance.
• Acute SNIP1 depletion + FHA‑domain mutant rescue in human cells (PMID:41904131) — quantitative proteomics of chromatin‑associated spliceosomes, iCLIP‑seq; directly tested the E366G variant and showed impaired P‑SF3B1 binding, splicing defects, and reduced cell viability. This is the definitive variant‑specific functional assay available.
• iPSC / organoid models: none published. Given the NPC‑apoptosis mechanism, patient‑derived iPSC cortical organoids are the obvious missing model — a strong candidate for a proposed_experiments entry in a KNOWLEDGE_GAP discussion.
• MorPhiC: SNIP1 is not among the named MorPhiC anchor genes (ISL1, EOMES, GCM1, NKX2‑1); no MorPhiC dataset applies.

15.4 Phenotype recapitulation and limitations

Limitations to record explicitly (candidate HUMAN_MODEL_MISMATCH discussion): 1. No E366G knock‑in mouse exists. Every in‑vivo model is a null or conditional null, whereas the human allele is a hypomorph. Null mice die prenatally; humans live to at least 26 years. Conclusions about the human disorder drawn from null models are therefore directionally informative but quantitatively wrong. 2. Nestin‑Cre deletion is neural‑restricted, so it cannot model the craniofacial, cardiac, airway, or endocrine components — i.e., the multisystem, "recognisable syndrome" part of the disease is entirely unmodelled. 3. Embryonic lethality precludes modelling epilepsy, the single most disabling human feature. 4. The PRC2‑depletion rescue was performed in a null background during embryogenesis — it does not establish that PRC2 inhibition would help a living patient with a hypomorphic allele. 5. Zebrafish snip1 mutants are studied as RES‑complex loss, not as a disease model per se.

15.5 Model resources

MGI (informatics.jax.org, MGI:2156003) · IMPC (Snip1^tm1a(EUCOMM)Wtsi) · Infrafrontier/EMMA line 04224 (the tm1a allele used in PMID:37553330) · EUCOMM/KOMP repositories · RGD (RGD:1359268) · ZFIN (zebrafish snip1/pml1 mutants from PMID:29969449) · Alliance of Genome Resources.

Appendix A — Consolidated reference list

Non‑PMID resources: GeneReviews NBK558237 (Wallace SE, Puffenberger EG, Bean LJH, "Genetic Disorders Associated with Founder Variants Common in the Amish Population," last update 2023‑12‑07) · OMIM #614501 and *608241 · ClinVar Variation 30717 / RCV000023695 · dbSNP rs387906986 · UniProt Q8TAD8 · HGNC:30587 · MGI:2156003 · IMPC · HPO disease annotations for OMIM:614501 (ontology.jax.org) · NCBI GTR (SNIP1 tests) · DDC Clinic Laboratory (Symptomatic Epilepsy and Skull Dysplasia targeted test) · Clinic for Special Children.

Appendix B — Curation gaps and open questions (candidate discussions entries)

Sources: PLOS Genetics — A biallelic SNIP1 Amish founder variant causes a recognizable neurodevelopmental disorder · PMC8496849 · PLOS One — Genetic mapping and exome sequencing identify variants associated with five novel diseases · OMIM #614501 · OMIM *608241 · ClinVar RCV000023695 · HPO annotations for OMIM:614501 · MONDO:0013787 via EBI OLS4 · HGNC SNIP1 · UniProt Q8TAD8 · MGI:2156003 Snip1 · IMPC Snip1 genotype–phenotype · GeneReviews — Genetic Disorders Associated with Founder Variants Common in the Amish Population (NBK558237) · PubMed 37553330 · PMC10409800 · PubMed 41904131 · PubMed 37027487 · PubMed 29969449 · PubMed 38304835 · PubMed 29726122 · NCBI GTR — SNIP1 tests · DDC Clinic Laboratory — Symptomatic Epilepsy and Skull Dysplasia (SNIP1) Targeted Testing · QuickGO · ClinicalTrials.gov API v2